Wanbury Limited Announces Q1 Results; Approves Employee Stock Option Allotment and Director Re-appointment

Wanbury Limited Announces Q1 Results; Approves Employee Stock Option Allotment and Director Re-appointment​

Wanbury Limited has released its un-audited financial results for the first quarter ended June 30, 2026, following a Board meeting held on August 11, 2026. The company also approved the allotment of equity shares pursuant to the exercise of vested options under the Wanbury ESOP 2016 and confirmed the re-appointment of Mr. Mohan Kumar Rayana as a Whole-time Director.

The unaudited financial results were reviewed by Chartered Accountants Kapoor & Parekh Associates, who provided a Limited Review Report on the Statement in accordance with SRE 2410.

Financial Performance Snapshot​

The company's performance for the quarter ended June 30, 2026, showed revenue from operations at ₹16,558.35 Lakhs. Profit after tax comprehensive income stood at (₹19.03) Lakhs. The diluted earnings per share (EPS) were reported at ₹0.92 for the quarter ended June 30, 2026.

A summary of the unaudited financial results is provided below:

ESOP Allotment and Capital Update​

The Board approved the allotment of 27,530 Equity Shares to eligible employees who exercised their vested options under the Wanbury ESOP 2016. These shares were allotted on August 11, 2026. The shares are issued with a face value of ₹10 each and the exercise price was set at ₹10 per option.

This allotment is set to increase the company's paid-up share capital from the previous amount of Rupees Thirty Four Crore Ninety Three Lakhs Ninety Three Thousand into Rs. 34,96,69,280, comprising 3,49,39,398 fully paid up Equity Shares of face value ₹10 each.

Director Appointment and Profile​

Mr. Mohan Kumar Rayana (DIN - 07878975) was re-appointed as a Whole-time Director for a term of five years, effective August 21, 2026, subject to shareholder approval.

Mr. Rayana has been associated with Wanbury Limited since its inception in 1988 and possesses over two decades of experience in corporate leadership and governance. His background includes a degree in Pharmacy from the University of Mumbai, and he served for more than 25 years in an advisory capacity at Wanbury. He brings extensive experience in business strategy, general management, acquisitions, mergers, fundraising, and debt settlement. Mr. Rayana is not related to any other directors of the company.

Operational and Financial Activities​

The company reported that it availed aggregate borrowings of Rs. 205 crores from non-banking financial companies (NBFCs) during the quarter for the purpose of repaying existing high-cost borrowings, capital expenditure, and general corporate purposes. Concurrently, 85,20,330 equity shares pledged by promoters to existing lenders were released on July 7, 2026.

In terms of international regulatory milestones, Wanbury Limited's two USFDA approved manufacturing facilities in Tanuku (Andhra Pradesh) and Patalganga (Maharashtra) successfully cleared inspections from the Therapeutic Goods Administration (TGA), Australia, and MFDS-Korea, respectively, with zero observations recorded.

WANBURY Stock Price Movement​

On Tuesday, shares of Wanbury Limited surged 4.94%, settling at ₹254.30 after closing strong against its previous close. The stock finished within a daily range defined by a low of ₹231.45 and a high of ₹258.85, amidst trading volume hitting 1.37 million shares.